



Department of Defense US Army Medical Research and Materiel Command

Fiscal Year 2002 Ovarian Cancer Research Program Awards List

Table of Contents

Introduction

Fiscal Year 2002 Ovarian Cancer Research Program Funded Awards

RESEARCH AWARDS

Idea Development Awards

TRAINING AWARDS

Institutional Training Grant

Fiscal Year 2002 Ovarian Cancer Research Program Participants

Peer Reviewers

Integration Panel Members

Ad Hoc Programmatic Reviewers

Glossary of Terms

INTRODUCTION

The US Army Medical Research and Materiel Command is pleased to present the award list of funded projects for the fiscal year 2002 (FY02) Ovarian Cancer Research Program. Award negotiations were completed on June 15, 2003. The awards listed in this document were selected by a competitive two-tiered review process. Funding decisions were based upon scientific excellence evaluated in the first tier of review, followed by programmatic relevance judged in the second tier. These projects represent a diverse portfolio of scientific research in four program emphasis areas: Etiology, prevention, early detection/diagnosis, and/or preclinical therapeutics.

Congressional direction for FY02 specified \$10.2 million for ovarian cancer research. Following the receipt of funds, a programmatic strategy was developed, proposals were solicited and evaluated, awards were selected, and contract negotiations were completed. The FY02 programmatic strategy called for Ovarian Cancer Idea Development Awards and Institutional Training Grants. The intent of the Idea Development Award is to encourage innovative approaches to ovarian cancer research, and the Institutional Training Grant is intended to support postdoctoral training programs in ovarian cancer research. FY02 funds are supporting 16 Idea Development Awards and one Institutional Training Grant.

As the funded investigators embark on these projects, the Department of Defense and the US Army gratefully acknowledge the participation of their scientist, clinical, and consumer advisors. The expertise, vision, and diversity of perspectives of all individuals who contributed to this program were vital to developing a sound investment strategy on behalf of all persons affected by ovarian cancer. It is with great anticipation and excitement that we await the outcomes of this research.

Idea Development Awards

| Log Number | Last Name | First Name | Institution | Proposal Title | Award Amount |
|------------|-------------|------------|---|--|--------------|
| OC020021 | Zhang | Xiaoliu | Baylor College of Medicine | A Fusogenic Oncolytic Herpes Simplex Virus for Therapy of Advanced Ovarian Cancer | \$380,324 |
| OC020037 | Simpkins | Henry | Temple University School of Medicine | The Role of Dihydrodiol Dehydrogenase in the Development of Resistance to Platinum Drugs in Ovarian Cancer | \$138,192 |
| OC020072 | Howell | Stephen | University of California, San Diego | Field-Deployable Ultra-Sensitive Assay | \$553,015 |
| OC020093 | Naora | Honami | University of Texas M.D. Anderson Cancer Center | Histogenesis of Epithelial Ovarian Tumors: Role of HOX Genes that Define Tissue Identity in the Primordial Female Reproductive Tract | \$562,251 |
| OC020099 | Sgouros | George | Johns Hopkins University, East Baltimore Campus | Therapy of Ovarian Carcinoma by Targeted Delivery of Alpha-Particles using Immunoliposomes Capable of Retaining Alpha-Emitting Daughters | \$579,816 |
| OC020113 | Keyomarsi | Khandan | University of Texas M.D. Anderson Cancer Center | The Role of Cyclin E and Its Lower Molecular Forms in the Oncogenesis of Ovarian Cancer and Its Predictive Value in Patients with Early Stage Ovarian Tumors | \$434,706 |
| OC020150 | Sikic | Branimir | Stanford University | Mechanisms of Taxane Resistance in Ovarian Carcinomas | \$588,705 |
| OC020173 | Zou | Weiping | Tulane University | SDF-1, DC1/DC2, and Tumor Angiogenesis | \$556,875 |
| OC020184 | Yamada | Seiko | University of Chicago | The Role of MKK4 in the Metastatic Colonization of Ovarian Cancer | \$556,755 |
| OC020187 | Behringer | Richard | University of Texas M.D. Anderson Cancer Center | Molecular Cloning, Characterization, and Knockout of the Mouse CA125 Gene | \$562,500 |
| OC020191 | Mills | Gordon | University of Texas M.D. Anderson Cancer Center | Detection of Serum Lysophosphatidic Acids Using Affinity Binding and Surface Enhanced Laser Desorption/Ionization (SELDI) Time of Flight Mass Spectrometry | \$497,838 |
| OC020196 | Santin | Alessandro | University of Arkansas for Medical Sciences | Novel Target Peptides for Ovarian Cancer Immunotherapy | \$505,123 |
| OC020220 | Godwin | Andrew | Fox Chase Cancer Center | Developing Inhibitors of Ovarian Cancer Progression by Targeted Disruption of the Gamma-Synuclein Activated Migratory and Survival Signaling Pathways | \$550,384 |
| OC020223 | Turchi | John | Wright State University | Proteomic Analysis of Cisplatin-Resistant Ovarian Cancers | \$343,257 |
| OC020242 | Martignetti | John | Mount Sinai School of Medicine, New York | A Novel Epithelial Ovarian Cancer Tumor Suppressor Gene | \$577,815 |
| OC020258 | Thompson | Winston | Morehouse School of Medicine | The Role and Action of Prohibitin, an Antiproliferative Gene, in Ovarian Cancer | \$421,725 |
| OC020259 | Mulder | Kathleen | Pennsylvania State University, Milton S. Hershey Medical Center | Development of km23-Based Diagnostics and Therapeutics | \$561,375 |

Institutional Training Grant

| Log Number | Last Name | First Name | Institution | Proposal Title | Award Amount |
|-------------------|------------------|-------------------|--------------------------------|--|---------------------|
| OC020137 | Seiden | Michael | Massachusetts General Hospital | Ovarian Cancer Training Program at the Dana-Farber/Harvard Cancer Center | \$600,000 |

Fiscal Year 2002 Ovarian Cancer Research Program Peer Reviewers

| Peer Reviewers | Degree | Institution/Affiliation |
|----------------------|-------------|---|
| Allworth, Ann | Ph.D. | Howard University |
| Bai, Wenlong | Ph.D. | University of South Florida |
| Baron, Andre | Ph.D. | Mayo Clinic Foundation |
| Batra, Surinder | Ph.D. | University of Nebraska |
| Beck, William | Ph.D. | University of Illinois at Chicago |
| Benbrook, Doris | Ph.D. | University of Oklahoma |
| Bieberich, Charles | Ph.D. | University of Maryland Baltimore County |
| Bigbee, William | Ph.D. | University of Pittsburgh |
| Blay, Jonathan | Ph.D. | Dalhousie University |
| Bouhassira, Eric | Ph.D. | Albert Einstein College of Medicine |
| Cannon, Martin | Ph.D. | University of Arkansas for Medical Sciences |
| Caperelli, Carol | Ph.D. | University of Cincinnati |
| Carter, JoAnn | Ed.D. | Ovarian Cancer National Alliance |
| Cheng, Jin | M.D., Ph.D. | University of South Florida |
| Crawford, Dana | Ph.D. | Albany Medical College |
| Curtin, John | M.D. | New York University |
| Dahiya, Rajvir | Ph.D. | University of California at San Francisco and VAMC |
| DiCioccio, Richard | Ph.D. | Roswell Park |
| Disis, Mary | M.D. | Fred Hutchinson Cancer Research Center |
| Dubeau, Louis | M.D., Ph.D. | University of Southern California |
| Edwards, Christopher | Ph.D. | Duke University |
| Elit, Laurie | M.D. | Hamilton Regional Cancer Centre |
| Figg, William | Pharm.D | National Cancer Institute/National Institutes of Health |
| Frey, Alan | Ph.D. | Princeton University |
| Godwin, Andrew | Ph.D. | Fox Chase Cancer Center |
| Golden, Catherine | Ph.D. | Ovarian Cancer National Alliance |
| Gulati, Jag | Ph.D. | Executive Secretary |
| Haber, Roberta | Ph.D. | Executive Secretary |
| Hallman, D. Michael | Ph.D. | University of Texas |

| Peer Reviewers | Degree | Institution/Affiliation |
|----------------------|---------------|--|
| Hickey, Robert | Ph.D. | Indiana University |
| Horowitz, Jonathan | Ph.D. | North Carolina State University |
| Huber, Mary | | National Ovarian Cancer Coalition |
| John, Gilbert | Ph.D. | Oklahoma State University |
| Johnson, Steven | Ph.D. | University of Pennsylvania |
| Kane, Madeleine | M.D., Ph.D. | University of Colorado |
| Klostergaard, Jim | Ph.D. | University of Texas M.D. Anderson Cancer Center |
| Knutson, Keith | Ph.D. | University of Washington |
| Kravit, Robyn | | Tethys Research LLC |
| Le, Tien | M.D. | Ottawa General Hospital |
| Listinsky, Catherine | M.D. | University of Alabama at Birmingham |
| Lum, Clark | Ph.D. | Executive Secretary |
| MacNee, Marjorie | M.A. | Sandy Rollman Ovarian Cancer Foundation |
| Miaux, Yves | M.D. | Synarc |
| Molina, Carlos | Ph.D. | University of Medicine and Dentistry of New Jersey |
| Mor, Gil | M.D., Ph.D. | Yale University |
| Mukhtar, Hasan | Ph.D. | University of Wisconsin |
| Nelson, James Arly | Ph.D. | University of Texas M.D. Anderson Cancer Center |
| Ochieng, Josiah | Ph.D. | Meharry Medical College |
| Olson, Janet | Ph.D. | Mayo Foundation & Clinic |
| Pardo, Francisco | M.D. | University of California-San Diego |
| Patrick, Sean | | Ovarian Cancer National Alliance |
| Reddy, Bandaru | D.V.M., Ph.D. | American Health Foundation |
| Richard, Nyrvah | | SHARE: Self Help for Women w/Breast or Ovarian Cancer |
| Rosen, Eliot | M.D., Ph.D. | Long Island Jewish Medical Center |
| Savage, Gale | M.D., M.P.H. | Executive Secretary |
| Schmitt, Mark | Ph.D. | State University of New York, Upstate Medical University |
| Schwanke, Jane | | Minnesota Ovarian Cancer Alliance, Inc. |
| Shabb, John | Ph.D. | University of North Dakota |

| Peer Reviewers | Degree | Institution/Affiliation |
|--------------------------|-------------|-------------------------------------|
| Siegal, Gene | M.D., Ph.D. | University of Alabama at Birmingham |
| Somplatsky-Jarman, Carol | | Ovarian Cancer National Alliance |
| Soprano, Kenneth | Ph.D. | Temple University |
| Stack, Mary Sharon | Ph.D. | Northwestern University |
| Syed, Viqar | Ph.D. | University of Massachusetts |
| Taylor, Christopher | Ph.D. | Georgetown University |
| Vigoreaux, Jim | Ph.D. | University of Vermont |
| Weiss, Geoffrey | M.D. | University of Texas |
| Whiteside, Theresa | Ph.D. | University of Pittsburgh |
| Wu, T.C. | M.D., Ph.D. | Johns Hopkins University |
| Xu, Xiangxi (Michael) | Ph.D. | Fox Chase Cancer Center |
| Xu, Yan | Ph.D. | Cleveland Clinic Foundation |

**Fiscal Year 2002 Ovarian Cancer Research Program
Integration Panel (IP) Members**

| IP Members | Degree | Institution/Affiliation |
|-----------------------------------|---------------|---|
| Karlan, Beth (Chair) | M.D. | Cedars-Sinai Medical Center |
| Alvarez, Ronald | M.D. | University of Alabama at Birmingham |
| Bell, Debra | M.D. | Massachusetts General Hospital |
| Boyd, Jeffrey | Ph.D. | Memorial Sloan-Kettering Cancer Center |
| Daly, Mary | M.D., Ph.D. | Fox Chase Cancer Center |
| Gershenson, David (Chair-Elect) | M.D. | University of Texas M.D. Anderson Cancer Center |
| Hamilton, Thomas | Ph.D. | Fox Chase Cancer Center |
| Hoskins, William (Chair-Emeritus) | M.D. | Cancer Institute at Memorial Health University Medical Center |
| Hricak, Hedvig | M.D., Ph.D. | Memorial Sloan-Kettering Cancer Center |
| Kolker, Ann | J.D. | Ovarian Cancer National Alliance |
| Markman, Maurie | M.D. | The Cleveland Clinic Foundation |
| Padilla, Geraldine | Ph.D. | University of California-San Francisco |
| Robinson, Elwood | Ph.D. | North Carolina Central University |
| Rubin, Stephen | M.D. | University of Pennsylvania |
| Scroggins, Mary | M.A. | Ovarian Cancer National Alliance |

**Fiscal Year 2002 Ovarian Cancer Research Program
Ad Hoc Programmatic Reviewers**

| Ad Hoc Reviewers | Degree | Institution/Affiliation |
|-------------------------|---------------|----------------------------------|
| Goldman, Patricia | | Ovarian Cancer National Alliance |
| Kohn, Elise | M.D. | National Cancer Institute |

Glossary of Terms

Idea Development Award: As stated in the fiscal year 2002 (FY02) Ovarian Cancer Research Program (OCRP) Program Announcement, the intent of the Idea Development Award is to encourage innovative approaches to ovarian cancer research. Idea Development Awards must address at least one of the program emphasis areas (i.e., etiology, prevention, early detection/diagnosis, and/or preclinical therapeutics). Investigators from all academic levels were eligible to submit proposals; however, preliminary data relevant to ovarian cancer research and the proposed project was required. Evidence of institutional support and commitment to foster the applicant's research career, such as the provision of access to adequate laboratory facilities and equipment was necessary.

Institutional Training Grant (ITG): As stated in the FY02 OCRP Program Announcement, the intent of the ITG is to support postdoctoral training programs in ovarian cancer research. These grants emphasize the training of postdoctoral trainees who have an underlying interest in ovarian cancer research. Eligible postdoctoral trainees should have been in the laboratory in which this research is to be performed no more than 2 years at the time of submission and may have up to 5 years of postdoctoral experience (exclusive of clinical residency or fellowship training). ITGs must address one or more program emphasis area (i.e., etiology, prevention, early detection/diagnosis, and preclinical therapeutics). ITG proposals also must address the following key aspects of the proposed postdoctoral training program: (1) The program vision and goals, (2) the program faculty, (3) the training program and trainees, and (4) the proposed research areas.